| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
Amiloride HCl dihydrate (MK870; MK-870; MK 870; Midamor; Midoride; Modamide), the hydrochloride salt and dihydrated form of amiloride, is a potent and selective epithelial sodium channel (ENaC) blocker that has been used since 1967 in the management of hypertension and congestive heart failure.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
A strong inhibitor of epithelial sodium channels (ENaCs) is amiloride hydrochloride dihydrate. Within fifteen to thirty minutes after injection, amiloride is significantly concentrated in the plasma. When compared to the baseline readings (n = 7), a 2 mg/kg dose of amiloride hydrochloride dihydrate has no effect on blood pressure, heart rate, mesenteric vascular resistance, or hindquarters vascular resistance. Amiloride hydrochloride dihydrate causes very little change in heart rate (-10±6 bpm/min) and arterial pressure (-1±1 mmHg) over a 2-hour period when compared to baseline values. The c-Fos activation in the area postrema (AP) exhibits a dose-related response pattern, according to the results. Amiloride hydrochloride dihydrate, even at the lowest dose of 0.1 mg/kg, is statistically different from the control rats in terms of the number of c-Fos labeled neurons at the p<0.01 level[1].
|
||
| Animal Protocol |
|
||
| References |
[1]. Miller RL, et al. Blockade of ENaCs by amiloride induces c-Fos activation of the area postrema. Brain Res. 2015 Mar 19;1601:40-51.
[2]. Xu LB, et al. Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes. Genet Mol Res. 2015 Aug 14;14(3):9518-29. [3]. Giamarchi A, et al. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J. 2010 Apr 7;29(7):1176-91 |
| Molecular Formula |
C6H8CLN7O.HCL.2H2O
|
|
|---|---|---|
| Molecular Weight |
302.12
|
|
| CAS # |
17440-83-4
|
|
| Related CAS # |
Amiloride hydrochloride;2016-88-8;Amiloride;2609-46-3
|
|
| SMILES |
ClC1C(N([H])[H])=NC(=C(C(/N=C(\N([H])[H])/N([H])[H])=O)N=1)N([H])[H].Cl[H].O([H])[H].O([H])[H]
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3099 mL | 16.5497 mL | 33.0994 mL | |
| 5 mM | 0.6620 mL | 3.3099 mL | 6.6199 mL | |
| 10 mM | 0.3310 mL | 1.6550 mL | 3.3099 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA